



UGT1A10 (h2): 293T Lysate: sc-116431

BACKGROUND

Glucuronidation, an important bile acid detoxification pathway, is catalyzed by enzymes belonging to the UDP-glucuronosyltransferase (UGT) superfamily. UGT genes are classified into the UGT1A and UGT2B subfamilies. Although each subfamily and each isoform shows tissue-specific patterns of distribution, the underlying mechanisms for this tissue specificity have not been fully elucidated. The human UDP-glucuronosyltransferase 1 (UGT1) locus encodes at least ten UGT1A proteins (UGT1A1-UGT1A10) that play a prominent role in drug and xenobiotic metabolism. Research indicates that nuclear receptors such as pregnane X receptor (PXR), constitutive androstane receptor (CAR) and peroxisome proliferator-activated receptor (PPAR) can regulate UGTs, which may contribute to the tissue-specific expression pattern of UGTs. Deficiency in the expression and/or activity of UGTs may lead to genetic and acquired diseases such as Crigler-Najjar syndrome and Gilbert syndrome. Based on their ability to catalyze the glucuronidation of xenobiotics and endobiotics, UGTs play a critical role in hormonal homeostasis, energy metabolism, bilirubin clearance and xenobiotic detoxification. UGT1A10 is an important detoxifier of polycyclic aromatic hydrocarbons, and the UGT1A10 codon 139 polymorphism may be an important risk determinant for tobacco-related cancers.

REFERENCES

1. Moghrabi, N., et al. 1992. Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase genes (UGT1A-subfamily). *Ann. Hum. Genet.* 56: 81-91.
2. Owens, I.S., et al. 1996. The novel UGT1 gene complex links bilirubin, xenobiotics, and therapeutic drug metabolism by encoding UDP-glucuronosyltransferase isozymes with a common carboxyl terminus. *J. Pharmacokinet. Biopharm.* 24: 491-508.
3. Ciotti, M., et al. 1997. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. *Am. J. Med. Genet.* 68: 173-178.
4. Strassburg, C.P., et al. 1997. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. *Cancer Res.* 57: 2979-2985.
5. Maruo, Y., et al. 2000. Prolonged unconjugated hyperbilirubinemia associated with breast milk and mutations of the bilirubin uridine diphosphate-glucuronosyltransferase gene. *Pediatrics* 106: E59.
6. Ohnishi, A. and Emi, Y. 2003. Rapid proteasomal degradation of translocation-deficient UDP-glucuronosyltransferase 1A1 proteins in patients with Crigler-Najjar type II. *Biochem. Biophys. Res. Commun.* 310: 735-741.
7. Basu, N.K., et al. 2004. Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. *J Biol Chem* 279: 28320-28329.
8. Thomas, S.S., et al. 2006. Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. *Hum. Mutat.* 27: 717.

CHROMOSOMAL LOCATION

Genetic locus: UGT1A10 (human) mapping to 2q37.1.

PRODUCT

UGT1A10 (h2): 293T Lysate represents a lysate of human UGT1A10 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

UGT1A10 (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive UGT1A10 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.